BAJAJ BROKING

Notification close image
No new Notification messages
card image
Smartworks Coworking Spaces IPO is Open!
Apply for the Smartworks Coworking Spaces IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Anthem Biosciences IPO: Things Smart Investors Need to Know

Anthem Biosciences Limited, incorporated in 2006, operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with integrated operations across drug discovery, development, and manufacturing. The company caters to a wide range of customers globally, from emerging biotech firms to established pharmaceutical companies. Its offerings include fermentation-based active pharmaceutical ingredients such as peptides, enzymes, probiotics, vitamin analogues, and biosimilars. As of September 30, 2024, the company was involved in 196 ongoing projects, which include discovery, early and late-phase development, and commercial manufacturing.

The company’s CRDMO platform is structured around five key modalities—RNAi, ADC, peptides, lipids, and oligonucleotides—and four manufacturing capabilities that include fermentation, flow chemistry, custom synthesis, and biotransformation. Anthem serves customers in over 44 countries and holds intellectual property in India and abroad, with multiple patent applications pending. With a team of 600 professionals from varied scientific backgrounds, the company derives revenue from CRDMO services and specialty ingredients production.

For more details, visit the Anthem Biosciences IPO page.

Anthem Biosciences IPO Details and Objectives

Details

Information

IPO Date

July 14, 2025 to July 16, 2025

Issue Size

5,95,61,404 shares

(aggregating up to ₹3,395.00 Cr)

Price Band

₹540 to ₹570 per share

Lot Size

26 shares

Listing At

BSE NSE

Purpose of the IPO

  • Carry out the Offer for Sale of up to [?] Equity Shares of face value of ? 2 each by the Selling Shareholders aggregating up to ? 33,950.00 million

  • Achieve the benefits of listing the Equity Shares on the Stock Exchanges

Timeline of Anthem Biosciences IPO

Event

Date

IPO Open Date

Mon, Jul 14, 2025

IPO Close Date

Wed, Jul 16, 2025

Tentative Allotment

Thu, Jul 17, 2025

Initiation of Refunds

Fri, Jul 18, 2025

Credit of Shares to Demat

Fri, Jul 18, 2025

Tentative Listing Date

Mon, Jul 21, 2025

Cut-off time for UPI mandate confirmation

5 PM on July 16, 2025

Pricing & Lot Size of Anthem Biosciences IPO

Price Band for the IPO

  • ₹540 to ₹570 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Retail (Min)

1

26

₹14,820

Retail (Max)

13

338

₹1,92,660

S-HNI (Min)

14

364

₹2,07,480

S-HNI (Max)

67

1,742

₹9,92,940

B-HNI (Min)

68

1,768

₹10,07,760

How to Apply for the Anthem Biosciences IPO?

Online Application Process

  • Log in to Your Trading Account
    Access your trading account through your broker’s platform.

  • Navigate to the IPO Section
    Go to the IPO section to view active IPO listings.

  • Select Anthem Biosciences IPO
    Find "Anthem Biosciences IPO" and click on the ‘Apply’ button.

  • Enter Application Details
    Specify the number of lots (minimum lot size: 26 shares) and the bid price within the range of ₹540 to ₹570 per share.

  • Provide Your UPI ID
    Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.

  • Review and Submit
    Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on July 16, 2025, to complete your application process.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹2,014.46 crore in FY23 to ₹2,807.58 crore as of March 2025.

  • Revenue: Reached ₹1,930.29 crore in FY25.

  • Profit After Tax (PAT): Stood at ₹451.26 crore for March 2025.

  • Net Worth: Recorded at ₹2,409.86 crore in FY25.

  • Reserves and Surplus: Recorded at ₹2,298.05 crore (March 2025), growing steadily over the years.

  • EBITDA: Stood at ₹683.78 crore in March 2025.

Recent Performance and Growth Prospects

  • The company has experienced consistent growth in its total assets over recent financial years.

  • Revenue generation has shown an upward trend, indicating increased business activity and market presence.

  • Profitability has improved, reflecting operational efficiency and cost management.

  • The company’s net worth has strengthened, supported by retained earnings and a solid capital base.

  • Reserves and surplus have grown steadily, suggesting effective financial planning and reinvestment.

  • Operating performance remains stable, with earnings before interest, taxes, depreciation, and amortisation showing healthy levels.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company’s business is exposed to regulatory changes and compliance requirements across different international markets, which may affect operations.

  • Success depends on ongoing R&D efforts, and a lower-than-expected transition of molecules from development to commercialisation could impact future revenue streams.

Opportunities and Growth Potential

  • Anthem Biosciences operates across multiple therapeutic platforms and offers end-to-end CRDMO services, positioning it to meet diverse client needs globally.

  • A growing international client base, pending patent applications, and specialised manufacturing capabilities support expansion in both CRDMO and specialty ingredient segments.

Key Performance Indicator (KPI)

KPI

Values

ROE

20.82%

ROCE

26.88%

Debt/Equity

0.05

RoNW

20.82%

PAT Margin

23.38%

EBITDA Margin

36.81%

Price to Book Value

13.23

Anthem Biosciences IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Kfin Technologies Limited

Jm Financial Limited 

Company Address of Anthem Biosciences Ltd

Anthem Biosciences Ltd.

No. 49, F1 & F2, Canara Bank Road

Bommasandra Industrial Area, Phase 1,

Bommasandra,

Bengaluru, Karnataka, 560099

Phone: +91 080 6672 400

Email: investors.abl@anthembio.com

Website: https://www.anthembio.com/

Conclusion

Anthem Biosciences Limited is engaged in offering contract research, development, and manufacturing services to a varied clientele across global markets. Its operations span multiple modalities and manufacturing technologies, supported by a team of professionals from different scientific fields. The company’s revenue sources include CRDMO services and specialty ingredients, with activities spread across discovery, development, and commercial manufacturing stages.

The upcoming IPO is structured as an Offer for Sale, with the objective of achieving a stock exchange listing. The company has shown growth in operational and financial metrics over recent years. Interested participants may consider the timeline, application process, and price band details before proceeding with the IPO application.

Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Anthem Biosciences IPO.

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|